Heron Therapeutics
HRTX
187 hedge funds and large institutions have $677M invested in Heron Therapeutics in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 76 increasing their positions, 47 reducing their positions, and 35 closing their positions.
202% more call options, than puts
Call options by funds: $7.75M | Put options by funds: $2.57M
62% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 47
0.51% more ownership
Funds ownership: 115.41% → 115.92% (+0.51%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 200 → 187 (-13)
37% less capital invested
Capital invested by funds: $1.07B → $677M (-$397M)
37% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$38.3M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$11.5M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$9.23M |
| 4 |
Morgan Stanley
New York
|
+$8.62M |
| 5 |
D.E. Shaw & Co
New York
|
+$5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$29.7M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$21.4M |
| 3 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
-$12.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$10.8M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.5M |
HRTX Hedge Fund Activity: Q1 2022 in Review
187 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2022, worth a combined $677M — down 37% from $1.07B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of HRTX and 22 opened new positions — a net loss of 13 holders — while 47 trimmed existing stakes and 76 added.
The largest buyer was State Street, adding an estimated $38.3M. The largest seller was Tang Capital Management, cutting an estimated $29.7M.
- 187 institutional investors held Heron Therapeutics (HRTX) as of Q1 2022, down from 200 in Q4 2021.
- Funds reported $677M of Heron Therapeutics stock for Q1 2022, down 37% quarter-over-quarter.
- 22 funds opened new Heron Therapeutics positions in Q1 2022 and 35 closed out, a net change of -13 holders.
- The largest Heron Therapeutics buyer in Q1 2022 was State Street, an estimated $38.3M added.
- The largest Heron Therapeutics seller in Q1 2022 was Tang Capital Management, an estimated $29.7M sold.
Based on aggregated 13F filings for Q1 2022.